Simulations Plus (NASDAQ: SLP) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, clinical development research, and regulatory submissions. We partner with companies to provide a data-driven, strategic modeling methodology, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. With our subsidiaries, Cognigen Corporation and DILIsym Services, we offer #1-ranked, easy-to-use software (GastroPlus®, ADMET Predictor®, KIWI™, DILIsym®, NAFLDsym®, PKPlus™, and more) to bridge data mining, compound library screening with machine learning models, PBPK/TK modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology/toxicology approaches.

Our software programs are complemented by our PBPK and pharmacometric modeling and simulation services, including model-driven drug development strategies, PK/PD modeling & simulation, and data assembly.

The Simulations Plus team of over 100 dedicated scientists & professionals, with decades of experience, stands ready to help.